Supplementary Figure 3. Cumulative incidence rates of HBeAg loss, complete virological response, and HCC in patients with and without HBeAg (A–C) and in patients treated with entecavir or tenofovir (D–F) (Kaplan-Meier plot). The cumulative incidence rates of HBeAg loss were calculated among HBeAg-positive patients (n=172). The cumulative incidence rates of CVR achievement were significantly higher in HBeAg-negative patients than in HBeAg-positive patients (P=0.001, log-rank test) (n=334). The cumulative incidence rates of HCC were significantly higher in HBeAg-negative patients than in HBeAg-positive patients (P=0.027, log-rank test) (n=334). In contrast, the cumulative incidence rates of CVR achievement, HBeAg loss among HBeAg-positive patients, and HCC were statistically similar (all P>0.05, log-rank test). HBeAg, hepatitis B e antigen; HCC, hepatocellular carcinoma; CVR, complete virological response.